266 related articles for article (PubMed ID: 19160361)
21. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection.
Chua TC; Yan TD; Zhao J; Morris DL
Eur J Surg Oncol; 2009 Dec; 35(12):1299-305. PubMed ID: 19632081
[TBL] [Abstract][Full Text] [Related]
22. Multimodality treatment of neuroendocrine liver metastases.
Karabulut K; Akyildiz HY; Lance C; Aucejo F; McLennan G; Agcaoglu O; Siperstein A; Berber E
Surgery; 2011 Aug; 150(2):316-25. PubMed ID: 21801968
[TBL] [Abstract][Full Text] [Related]
23. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.
McStay MK; Maudgil D; Williams M; Tibballs JM; Watkinson AF; Caplin ME; Buscombe JR
Radiology; 2005 Nov; 237(2):718-26. PubMed ID: 16192318
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic neuroendocrine tumors: presentation, management, and outcomes.
Nissen NN; Kim AS; Yu R; Wolin EM; Friedman ML; Lo SK; Wachsman AM; Colquhoun SD
Am Surg; 2009 Oct; 75(10):1025-9. PubMed ID: 19886158
[TBL] [Abstract][Full Text] [Related]
25. 31P MR spectroscopy to evaluate the efficacy of hepatic artery embolization in the treatment of neuroendocrine liver metastases.
Ljungberg M; Westberg G; Vikhoff-Baaz B; Starck G; Wängberg B; Ekholm S; Ahlman H; Forssell-Aronsson E
Acta Radiol; 2012 Dec; 53(10):1118-26. PubMed ID: 23051638
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.
Fischer L; Kleeff J; Esposito I; Hinz U; Zimmermann A; Friess H; Büchler MW
Br J Surg; 2008 May; 95(5):627-35. PubMed ID: 18306152
[TBL] [Abstract][Full Text] [Related]
27. Radiofrequency ablation of neuroendocrine hepatic metastasis.
Gamblin TC; Christians K; Pappas SG
Surg Oncol Clin N Am; 2011 Apr; 20(2):273-9, vii-viii. PubMed ID: 21377583
[TBL] [Abstract][Full Text] [Related]
28. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center.
Carpizo DR; Are C; Jarnagin W; Dematteo R; Fong Y; Gönen M; Blumgart L; D'Angelica M
Ann Surg Oncol; 2009 Aug; 16(8):2138-46. PubMed ID: 19495884
[TBL] [Abstract][Full Text] [Related]
29. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
Nakakura EK; Venook AP; Bergsland EK
Surg Oncol Clin N Am; 2007 Jul; 16(3):639-51, x. PubMed ID: 17606198
[TBL] [Abstract][Full Text] [Related]
30. Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease.
Liu DM; Kennedy A; Turner D; Rose SC; Kee ST; Whiting S; Murthy R; Nutting C; Heran M; Lewandowski R; Knight J; Gulec S; Salem R
Am J Clin Oncol; 2009 Apr; 32(2):200-15. PubMed ID: 19346815
[No Abstract] [Full Text] [Related]
31. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.
Scigliano S; Lebtahi R; Maire F; Stievenart JL; Kianmanesh R; Sauvanet A; Vullierme MP; Couvelard A; Belghiti J; Ruszniewski P; Le Guludec D
Endocr Relat Cancer; 2009 Sep; 16(3):977-90. PubMed ID: 19470616
[TBL] [Abstract][Full Text] [Related]
32. [Interventional therapy of neuroendokrine tumors of the gastrointestinal tract].
Kettenbach J; Müller SL; Schindl M
Wien Klin Wochenschr; 2003; 115 Suppl 2():56-64. PubMed ID: 15518148
[TBL] [Abstract][Full Text] [Related]
33. Hepatic-directed Therapies in Patients with Neuroendocrine Tumors.
Kennedy AS
Hematol Oncol Clin North Am; 2016 Feb; 30(1):193-207. PubMed ID: 26614377
[TBL] [Abstract][Full Text] [Related]
34. Hepatic lymph node dissection provides a survival benefit for patients with nodal disease of colorectal carcinoma liver metastases.
Wakai T; Shirai Y; Sakata J; Nagahashi M; Kaneko K; Hatakeyama K
Hepatogastroenterology; 2009; 56(89):186-90. PubMed ID: 19453055
[TBL] [Abstract][Full Text] [Related]
35. Catheter-based treatments for hepatic metastases from neuroendocrine tumors.
Kolbeck KJ; Farsad K
AJR Am J Roentgenol; 2014 Oct; 203(4):717-24. PubMed ID: 25247935
[TBL] [Abstract][Full Text] [Related]
36. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver.
Wang SC; Fidelman N; Nakakura EK
Semin Oncol; 2013 Feb; 40(1):69-74. PubMed ID: 23391114
[TBL] [Abstract][Full Text] [Related]
37. [Radiofrequency ablation of colorectal liver metastases].
Vyslouzil K; Klementa I; Starý L; Zboril P; Skalický P; Dlouhý M; Cwiertka K; Duda M
Zentralbl Chir; 2009 Apr; 134(2):145-8. PubMed ID: 19382045
[TBL] [Abstract][Full Text] [Related]
38. Gastric cancer: correlation between clinicopathological factors and survival of patients (III).
Lazăr D; Tăban S; Sporea I; Dema A; Cornianu M; Lazăr E; Goldiş A; Vernic C
Rom J Morphol Embryol; 2009; 50(3):369-79. PubMed ID: 19690762
[TBL] [Abstract][Full Text] [Related]
39. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey.
Tiberio GA; Coniglio A; Marchet A; Marrelli D; Giacopuzzi S; Baiocchi L; Roviello F; de Manzoni G; Nitti D; Giulini SM
Eur J Surg Oncol; 2009 May; 35(5):486-91. PubMed ID: 19171450
[TBL] [Abstract][Full Text] [Related]
40. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
